ETX 407
Alternative Names: ETX-407Latest Information Update: 27 Oct 2023
Price :
$50 *
At a glance
- Originator e-Therapeutics
- Class Amides; Amino sugars; Drug conjugates; Eye disorder therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Dry age-related macular degeneration
Most Recent Events
- 27 Oct 2023 ETX 407 is available for licensing as of 27 Oct 2023. https://www.etherapeutics.co.uk/our-science/therapeutic-pipeline/ (e-Therapeutics website, October 2023)
- 27 Oct 2023 Preclinical trials in Dry age related macular degenration in United Kingdom (SC), before October 2023 (e-Therapeutics pipeline, October 2023)